Cefadroxil
| Clinical data | |
|---|---|
| Trade names | Duricef | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682730 | 
| Routes of administration | Oral | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Protein binding | plasma protein | 
| Metabolism | unknown | 
| Elimination half-life | 1.5 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.397 | 
| Chemical and physical data | |
| Formula | C16H17N3O5S | 
| Molar mass | 363.39 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Cefadroxil (formerly trademarked as Duricef) is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections. It is a bactericidal antibiotic.
It was patented in 1967 and approved for medical use in 1978.